Trial Profile

A chronic multiple ascending dose phase Ib trial of Coversin in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Dec 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nomacopan (Primary)
Indications Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
Focus Adverse reactions

Most Recent Events

05 Dec 2016 Results published in an Akari Therapeutics media release.
12 Sep 2016 According to an Akari Therapeutics media release, the US FDA granted an orphan drug designation to coversin for the treatment of PNH.
06 Jul 2016 According to Akari Therapeutics media release, this trial is being conducted at Hammersmith Medicines Research Ltd, in London.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com